Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

NCT05254314 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help improve asthma control in adults who have both obesity and persistent asthma symptoms.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2022-10 · est. completion 2026-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05254314 ↗

Description as written by the study sponsor.

This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.

Treatments tested

Semaglutide Pen Injector 2.4mg weekly also known as Wegovy Drug

Once weekly subcutaneous injection
Placebo Other

Once weekly subcutaneous injection

Main thing measured	The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity.
Sponsor	Vanderbilt University Medical Center
Conditions studied	Asthma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05254314 ↗